US FDA Preparing For New 'Combination Product Agreement Meetings'
Executive Summary
Cures legislation offers more development certainty for sponsors by allowing informal agreements with the agency on pre- and postmarket issues.
You may also be interested in...
PDUFA VII: Will Gene Therapy's Rise Influence Talks?
The Center for Biologics Evaluation and Research may need more fee revenue to add employees to handle the increasing cell and gene therapy workload.
FDA's Drug Center Permits Some Combo Product Software To Be Submitted As DMFs
New draft guidance from the US agency allows electronics or software that will be used across multiple combination products to be submitted as a Type V drug master file (DMF), potentially streamlining the assessment process.
CDER Permits Some Combo Product Software To Be Submitted As DMFs
New draft guidance allows electronics or software that will be used across multiple combination products to be submitted as a Type V drug master file, potentially streamlining the assessment process.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: